Waldmann-Beushausen, Regina

[["dc.bibliographiccitation.firstpage","270"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oncology"],["dc.bibliographiccitation.lastpage","278"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Arnemann, Johanna"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Reuter-Jessen, Kirsten"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.date.accessioned","2019-01-29T11:57:51Z"],["dc.date.available","2019-01-29T11:57:51Z"],["dc.date.issued","2017"],["dc.description.abstract","ATP-binding cassette transport protein A3 (ABCA3) is expressed in non-small cell lung cancer (NSCLC). We hypothesize that high-level ABCA3 expression may have a negative prognostic impact in patients with NSCLC."],["dc.identifier.doi","10.1159/000477619"],["dc.identifier.pmid","28683465"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57421"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","final"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0232"],["dc.relation.issn","0030-2414"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","ABCA3 Phenotype in Non-Small Cell Lung Cancer Indicates Poor Outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","362"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Oncology"],["dc.bibliographiccitation.lastpage","370"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hupfeld, Timo"],["dc.contributor.author","Krause, Doris"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Guedenzoph, Bjoern"],["dc.contributor.author","Aung, Thiha"],["dc.contributor.author","Inagaki, Nobuya"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Danner, Bernhard Christoph"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Wulf, Gerald G."],["dc.date.accessioned","2018-11-07T09:29:56Z"],["dc.date.available","2018-11-07T09:29:56Z"],["dc.date.issued","2013"],["dc.description.abstract","Patients with advanced-stage bronchial cancer benefit from systemic cytostatic therapy, in particular from regimens integrating cisplatin and taxanes. However, eventual disease progression leads to a fatal outcome in most cases, originating from tumor cells resisting chemotherapy. We here show that the intracellular ATP-binding cassette transporter A3 (ABCA3), previously recognized as critical for the secretion of surfactant components from type 2 pneumocytes, is expressed in non-small-cell lung cancer (NSCLC) cells. With some heterogeneity in a given specimen, expression levels detected immunohistochemically in primary cancer tissue were highest in adenocarcinomas and lowest in small cell lung cancers. Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). Taken together, ABCA3 emerges as a modulator of NSCLC cell susceptibility to cytostatic therapy. Copyright (c) 2013 S. Karger AG, Basel"],["dc.description.sponsorship","Faculty of Medicine, Georg August University Gottingen, Germany"],["dc.identifier.doi","10.1159/000348884"],["dc.identifier.isi","000320219100007"],["dc.identifier.pmid","23689165"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10826"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31175"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0030-2414"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Intracellular ATP-Binding Cassette Transporter A3 is Expressed in Lung Cancer Cells and Modulates Susceptibility to Cisplatin and Paclitaxel"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","170"],["dc.bibliographiccitation.journal","Journal of Cardiothoracic Surgery"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Tirilomis, Theodor"],["dc.contributor.author","Bensch, Marc"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.date.accessioned","2018-11-07T09:48:49Z"],["dc.date.available","2018-11-07T09:48:49Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Early after neonatal cardiac surgery hemodynamic dysfunction may be evident. However, still is not clear if dysfunction and outcome is related to visible myocardial alterations. The aim of the present study was the histological analysis of myocardial tissue of neonatal piglets after cardiopulmonary bypass (CPB) and cardioplegic arrest. Methods: Neonatal piglets (younger than 7 days) were connected to CPB for 180 min, including 90 min of cardioplegic heart arrest at 32 degrees C. After termination of CPB the piglets were observed up to 6 h. During this observational period animals did not receive any inotropic support. Some piglets died within this period and formed the non-survivors group (CPB-NS group) and the remaining animals formed the CPB-6 h group. Myocardial biopsies (stained with H&E) were scored from 0 to 3 regarding histological alterations. Then, the histological data were evaluated and compared to the probes of animals handled comparable to previous piglets but without CPB (non-CPB group; n = 3) and to sibling piglets without specific treatment (control; n = 5). Results: In the first hours after CPB six piglets out of 10 died (median 3.3 h). The animals of CPB-6 h group (n = 4) were sacrificed at the end of experiments (6 h after CPB). Although the myocardial histological score of CPB-6 h group and CPB-NS group were higher than non-CPB group (2.0 +/- 0.8, 1.5 +/- 0.9, and 0.8 +/- 0.3 respectively), these differences were statistically not significant. But compared to control animals (score 0.3 +/- 0.5) the scores of CPB-6 h and CPB-NS groups were significantly higher (p < 0.05). Between the left and the right ventricular tissue there were no significant differences. Conclusions: Myocardial tissue alterations in newborn piglets are related to the surgical trauma and potentiated by cardiopulmonary bypass and ischemia. However, outcome is not related to the degree of tissue alteration."],["dc.description.sponsorship","Open-Access Publikationsfonds 2015"],["dc.identifier.doi","10.1186/s13019-015-0380-0"],["dc.identifier.isi","000365338900003"],["dc.identifier.pmid","26589394"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12541"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35388"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1749-8090"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Myocardial histology and outcome after cardiopulmonary bypass of neonatal piglets"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","21"],["dc.bibliographiccitation.issue","03"],["dc.bibliographiccitation.journal","Advances in Lung Cancer"],["dc.bibliographiccitation.lastpage","29"],["dc.bibliographiccitation.volume","05"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Oellerich, Angelika"],["dc.contributor.author","Füzesi, Laszlo"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Danner, Bernhard C."],["dc.date.accessioned","2019-07-09T11:43:03Z"],["dc.date.available","2019-07-09T11:43:03Z"],["dc.date.issued","2016"],["dc.description.abstract","Non-small cell lung cancer (NSCLC) is the primary cause of cancer related death worldwide. After resection of early stage NSCLC, the benefit of adjuvant chemotherapy for patient survival still remains unclear and investigations for further risk stratification are needed for an improved treatment decision. Microvessel density (MVD) influences both the nutrition of the cancer and the access to the bloodstream for the development of distant metastasis. The aim of this study was to examine the prognostic significance of microvessel density by CD31 staining in patients with resected stage IA-IIIB NSCLC. We used immunohistochemistry (IHC) of CD31 to examine the microvessel density in a cohort of 69 patients who had undergone radical resection for NSCLC. Correlation of IHC values and standard clinicopathologic parameters was analyzed as well as influence on long term survival. Survival analysis revealed a significant better overall survival for patients with higher median microvessel density (log rank p = 0.031) independent of clinicopathologic parameters. Regarding primary cancer related death, the survival was again significantly longer in patients with high CD31 count (log rank p = 0.036). A higher microvessel density was a strong predictor for a longer tumor related survival and could be used for therapeutic decisions of adjuvant chemotherapy after resection of early stage NSCLC."],["dc.identifier.doi","10.4236/alc.2016.53003"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14089"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58810"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2169-2726"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Prognostic Significance of CD31 Expression in Patients with Non-Small-Cell-Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","30"],["dc.bibliographiccitation.issue","03"],["dc.bibliographiccitation.journal","Advances in Lung Cancer"],["dc.bibliographiccitation.lastpage","38"],["dc.bibliographiccitation.volume","05"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Oellerich, Angelika"],["dc.contributor.author","Füzesi, Laszlo"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Danner, Bernhard C."],["dc.date.accessioned","2019-07-09T11:43:02Z"],["dc.date.available","2019-07-09T11:43:02Z"],["dc.date.issued","2016"],["dc.description.abstract","The aims of this study were to examine prognostic significance of pigment epithelium- derived factor (PEDF) in patients with stage IA-IIIB non-small cell lung cancer (NSCLC). Using immunohistochemistry and multivariate analysis, we set out to investigate whether PEDF expression could provide prognostic information in NSCLC in a cohort of 69 patients who had undergone radical resection for NSCLC. The correlation between PEDF and the clinical pathological features of stage I-III NSCLC after radical surgery were analyzed as well as influence on long term survival. No correlation between PEDF intensity, PEDF area or PEDF area index and clinic opathologic parameters was seen. PEDF values showed a slight correlation to the tumor stage. There was a significant negative correlation (T = −0.288, p = 0.002) between pathologic T-stage and median PEDF area and vice versa a positive correlation (T = 0.227, p = 0.016) with median PEDF intensity. We could not detect any correlation between PEDF and long term survival. For PEDF analysis, there was only a slight correlation between expression and T-stage of the tumor."],["dc.identifier.doi","10.4236/alc.2016.53004"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14088"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58809"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2169-2726"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Prognostic Significance of Pigment Epithelium-Derived Factor Expression in Patients with Non-Small-Cell-Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]